Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Operating Leases (2021 - 2025)

Roivant Sciences (ROIV) has disclosed Operating Leases for 5 consecutive years, with $98.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Leases rose 8.87% year-over-year to $98.5 million, compared with a TTM value of $98.5 million through Dec 2025, up 8.87%, and an annual FY2025 reading of $90.3 million, up 100.64% over the prior year.
  • Operating Leases was $98.5 million for Q4 2025 at Roivant Sciences, up from $89.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $98.5 million in Q4 2025 and bottomed at $43.2 million in Q3 2024.
  • Average Operating Leases over 5 years is $64.1 million, with a median of $61.2 million recorded in 2021.
  • The sharpest move saw Operating Leases decreased 17.06% in 2022, then surged 108.02% in 2025.
  • Year by year, Operating Leases stood at $62.1 million in 2021, then decreased by 11.54% to $54.9 million in 2022, then dropped by 14.32% to $47.1 million in 2023, then skyrocketed by 92.27% to $90.5 million in 2024, then rose by 8.87% to $98.5 million in 2025.
  • Business Quant data shows Operating Leases for ROIV at $98.5 million in Q4 2025, $89.8 million in Q3 2025, and $90.3 million in Q2 2025.